CD274 and small cell lung carcinoma: B-NIT shows theoretical promise in SCLC, with advanced conjugates already developed—including neutron-triggered boron capsules, boron-rich polyboronate-ester micelles, and PD-L1 siRNA–loaded boron nanoparticles designed to elicit systemic antitumor immunity (108, 109, 113).